ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. Our primary focus is on two orphan diseases: the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.
Location: United States, New York, Village of Ardsley
Employees: 1-10
Total raised: $35M
Founded date: 2006
Investors 3
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| 30.10.2023 | Kurma Part... | kurmapartn... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.12.2021 | Series B | $35M | - |
Mentions in press and media 5
| Date | Title | Description |
| 03.01.2022 | Armgo Pharma Raises $35M in Funding | Armgo Pharma, an Ardsley, New York-based novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders, closed a $35m financing round. The round was led by Forbion with participatio... |
| 21.12.2021 | ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases | Ardsley, NY – December 20, 2021 – ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders today announced that it has completed a $35 mil... |
| 20.12.2021 | Forbion leads $35M Series B for ARMGO Pharma | Amsterdam, The Netherlands – 20th December 2021 – Forbion, a leading European life sciences venture capital firm, today announces that it has led a $35M series B financing in ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therap... |
| 20.12.2021 | ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases | ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases Series B investment led by Forbion and joined by Pontifax and Kurma Partners Investment will fund clinical studies ... |
| 20.12.2021 | ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases | ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases Series B investment led by Forbion and joined by Pontifax and Kurma Partners Investment will fund clinical studies ... |